# Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

> **NCT01425008** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 149 (actual)

## Conditions studied

- Melanoma
- Metastatic Melanoma
- Solid Tumor
- Neoplasm

## Interventions

- **DRUG:** MLN2480

## Key facts

- **NCT ID:** NCT01425008
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-15
- **Primary completion:** 2017-04-11
- **Final completion:** 2018-10-16
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01425008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01425008, "Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01425008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*